HISUN(SH:600267)2022-03-28 16:00Financial Performance - The company's operating revenue for 2021 was approximately ¥12.14 billion, representing a 6.89% increase compared to ¥11.35 billion in 2020[21]. - Net profit attributable to shareholders was approximately ¥486.89 million, a 16.71% increase from ¥417.19 million in 2020[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥210.27 million, a significant increase of 277.94% from ¥55.64 million in 2020[21]. - The weighted average return on equity increased to 7.49%, up by 1.03 percentage points from 6.46% in 2020[22]. - The total assets decreased by 7.12% to approximately ¥19.37 billion from ¥20.86 billion in 2020[21]. - The net cash flow from operating activities for 2021 was approximately ¥1.74 billion, a 9.24% increase from ¥1.59 billion in 2020[21]. - The basic earnings per share remained stable at ¥0.43, unchanged from 2020[22]. - The company achieved a total revenue of 12.136 billion, representing a growth of 6.89% compared to 2020, with main business revenue reaching 11.902 billion, an increase of 8.91%[53]. - The net profit attributable to the parent company was 487 million, an increase of 70 million from 2020, with a net profit of 210 million after deducting non-recurring gains and losses[53]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 1.4 RMB per 10 shares, totaling approximately 166.34 million RMB, which represents 34.16% of the net profit attributable to shareholders for 2021[4]. - The company reported a total of 7,869,859 shares repurchased, which will not participate in this profit distribution[5]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or their affiliates[6]. Risk Management and Compliance - The company has outlined potential risks in its report, which are detailed in the "Management Discussion and Analysis" section[6]. - The company has a comprehensive risk disclosure in its annual report[6]. - The company emphasizes the importance of accurate and complete financial reporting, as stated by its management[4]. - The company has not violated any decision-making procedures regarding external guarantees[6]. - The company received a standard unqualified audit report from Tianjian Accounting Firm[4]. Research and Development - The company filed 87 patent applications during the reporting period, with 47 patents granted, indicating a strong focus on innovation and intellectual property[35]. - The company launched nine capitalized R&D projects, including HS25, which successfully entered the market during the reporting period[77]. - The company has several key R&D projects in Phase I clinical trials, including HS234, HS236, HS269, HS301, and HS336, all targeting oncology indications[117]. - The total R&D investment for the year was approximately $4.4 million, accounting for 3.63% of total revenue, with a slight decrease from $4.59 million in the previous year[116]. Product Development and Market Expansion - The company is actively expanding into new business units, including strategic partnerships to strengthen its market position[40]. - The company has successfully launched new products, including the first domestic internal and external parasite control drops, achieving over 100 million yuan in sales[39]. - The company is focusing on expanding its product offerings in the pharmaceutical sector, including chemical raw materials and biological preparations[95]. - The company plans to enhance its product pipeline and reduce costs through integrated production of active pharmaceutical ingredients and formulations, aiming for competitive advantages in the market[100]. Corporate Governance - The company maintains a governance structure that complies with relevant laws and regulations, ensuring effective checks and balances among shareholders, the board, and management[159]. - The company emphasizes investor relations management, utilizing multiple channels for communication to ensure investors are well-informed[161]. - The company held four temporary shareholder meetings in 2021, all of which passed resolutions without any dissenting opinions[165][166][168]. Financial Health and Investments - The company’s debt levels have decreased, leading to a reduction in financing-related expenses year-on-year[53]. - The company reduced interest-bearing liabilities from 8.189 billion RMB in 2020 to 6.388 billion RMB in 2021, a decrease of 1.801 billion RMB[60]. - The company has completed significant non-equity investments totaling RMB 113.67 million, with various projects in production and registration phases[140]. - The company is investing heavily in R&D, with a budget increase of 25% to enhance product development and innovation[174]. Market Trends and Industry Outlook - The pharmaceutical industry in China saw a 20.1% increase in revenue and a 77.9% increase in total profit in 2021, indicating a strong recovery post-pandemic[43]. - The chemical drug formulation market in China is experiencing rapid growth due to increased public healthcare investment and rising living standards, with a focus on innovation and intellectual property protection[99]. - The biopharmaceutical industry is expected to continue driving rapid growth in the upstream supply chain over the next few years[98]. Employee Engagement and Corporate Culture - The company has implemented measures to enhance the management of insider information to prevent insider trading[165]. - The company conducted a comprehensive training program covering various topics, including GMP/EHS and project management, to enhance employee skills[196]. - The total remuneration for all directors, supervisors, and senior management in the reporting period amounted to CNY 19.2928 million[178]. Strategic Initiatives and Future Plans - The company plans to continue expanding its product offerings and market presence, focusing on new product development and strategic partnerships[67]. - The company aims for a consolidated revenue target of 12.5 billion yuan in 2022, representing a year-on-year increase of 3%[149]. - The company is considering strategic acquisitions to bolster its product portfolio, with potential targets identified in the biotech sector[174].